BBK Worldwide Launches the Engagement Solution Center for Decentralized and Post-Marketing Clinical Trial Success
Concierge Service Delivery and Robust Patient Experience Portal Ease Clinical Trial Journey
The COVID-19 pandemic has significantly accelerated the need to reshape research and development. Most specifically, it has led to demand for increased funding for decentralized and larger randomized clinical trials to inform clinical decisions and guide future research.
By launching the Engagement Solution Center, BBK Worldwide (BBK) is making patient-centric and inclusive trials an immediate and actionable reality for study sponsors.
3 Decentralized Clinical Trial Solutions Trending Now
Ever wonder which products and services study sponsors are leveraging for enrollment and engagement success? We thought we would take a moment to share the products and services gaining traction with our clients who are embracing decentralized clinical trials. And while it's always important to keep in mind that each study protocol is unique and requires its own analysis to determine the right solutions, we're sharing three popular ones below.
We recently sat down with BBK’s Global Strategist Amanda Moody to discuss the company’s commitment to Parkinson’s disease clinical research, including ongoing innovation designed to foster a positive and meaningful patient journey.
Can you briefly describe BBK’s experience with the Parkinson’s disease community?
We have a long-standing commitment to the Parkinson’s community, both in terms of supporting clinical research as well as individual patient and caregiver needs.
Earlier this week, Elizabeth Gargill went one-on-one with Outsourcing-Pharma, discussing findings from BBK's recent Study Voices survey that reveal shifts in healthcare consumer attitudes and behaviors since the onset of COVID-19. In this in-depth interview, Elizabeth discusses why clinical trial innovation is more important now than ever before and how clinical trial sponsors can leverage the survey findings to enhance their enrollment and engagement efforts.
As we navigate COVID-19 and beyond, understanding the patient voice is critical to overcoming clinical trial enrollment and engagement challenges. Our Study Voices infographic series sheds light on the patient voice, providing clinical trial sponsors with insight to help enhance the patient experience.
In today's one-minute video update, Mike Johnson, Director of RSG® Services, discusses how BBK's Patient Visit Support Services helped patients in Brazil receive their study medication despite the COVID-19 lockdown.
We recently had the opportunity to sit down with Lauren Lawhon, chief operating officer for Health Union, to discuss our newly formed partnership with the pioneer in online communities and how greater insight into the patient voice can enhance the clinical trial patient experience.
BBK Worldwide is honored to announce that our Principal and Director of Accounts and Site Services, David B. Fleishman, has been named to the 2019 PharmaVOICE 100 list of the most inspiring people in the life sciences industry for representing the best of the new generation of thought leaders. The award recognizes Mr. Fleishman for how he inspires and motivates those around him, his influence as a corporate leader, and his positive impact on the industry through his actions.
As originally conceived, personalized medicine referred to the tailoring of medical treatment to the individual characteristics of each patient. The right drug for the right patient at the right time has since evolved to an approach that takes into account individual differences in people’s genes, environments, and lifestyles.
While most large pharma companies seem “very open” to new technologies, a recent FiercePharma article also notes that the life science industry hasn’t exactly won accolades for its speed in adopting new artificial intelligence and machine learning technologies. However, since patient lives are at stake, the industry has good reason to proceed with caution.*
Dena Raffa, Director, Account Operations and BBK’s expert in digital innovation, shares her view on the complex topic of AI and machine learning technologies in life sciences.